Change in pathway – ronapreve

December 1, 2021

Ronapreve (a neutralising monoclonal antibody therapy) is now available for COVID-19 positive patients that are aged more than 12 years and weigh more than 40kgs. Positive patients that are unwell and well could be eligible to receive Ronapreve. Be sure to check out this short video featuring Dr Chizo Agwu, Deputy Medical Director to learn about the new pathway and how your patients can benefit from this treatment.

Note: All pathways including the full Neutralising Monoclonal Antibody (nMAB) (Casirivimab and Imdevimab) Ronapreve in Hospitalised Patients guidance can be found on the Covid Clinical Guidance page.